D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism.
Identifieur interne : 000609 ( PubMed/Corpus ); précédent : 000608; suivant : 000610D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism.
Auteurs : Carole Hyacinthe ; Quentin Barraud ; François Tison ; Erwan Bezard ; Imad GhorayebSource :
- Neurobiology of disease [ 1095-953X ] ; 2014.
English descriptors
- KwdEn :
- 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine (therapeutic use), Analysis of Variance, Animals, Disease Models, Animal, Dopamine Agonists (therapeutic use), Dose-Response Relationship, Drug, Electrocardiography, Electroencephalography, Electromyography, Female, Levodopa (therapeutic use), Macaca fascicularis, Macaca mulatta, Parkinsonian Disorders (complications), Parkinsonian Disorders (drug therapy), Quinpirole (therapeutic use), Sleep (drug effects), Sleep Disorders, Circadian Rhythm (drug therapy), Sleep Disorders, Circadian Rhythm (etiology), Telemetry, Time Factors, Wakefulness (drug effects).
- MESH :
- chemical , therapeutic use : 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine, Dopamine Agonists, Levodopa, Quinpirole.
- complications : Parkinsonian Disorders.
- drug effects : Sleep, Wakefulness.
- drug therapy : Parkinsonian Disorders, Sleep Disorders, Circadian Rhythm.
- etiology : Sleep Disorders, Circadian Rhythm.
- Analysis of Variance, Animals, Disease Models, Animal, Dose-Response Relationship, Drug, Electrocardiography, Electroencephalography, Electromyography, Female, Macaca fascicularis, Macaca mulatta, Telemetry, Time Factors.
Abstract
Both excessive daytime sleepiness (EDS) and rapid eye movement (REM) sleep deregulation are part of Parkinson's disease (PD) non-motor symptoms and may complicate dopamine replacement therapy. We report here that dopamine agonists act differentially on sleep architecture in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine macaque monkey. Continuous sleep and wake electroencephalographic monitoring revealed no effect of the selective dopamine D2 receptor agonist quinpirole on EDS, whereas the selective dopamine D1 receptor agonist SKF38393 efficiently alleviated EDS and restored REM sleep to baseline values. The present results question the relevance of abandoning D1 receptor agonist treatment in PD as it might actually improve sleep-related disorders.
DOI: 10.1016/j.nbd.2013.10.029
PubMed: 24211719
Links to Exploration step
pubmed:24211719Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism.</title><author><name sortKey="Hyacinthe, Carole" sort="Hyacinthe, Carole" uniqKey="Hyacinthe C" first="Carole" last="Hyacinthe">Carole Hyacinthe</name><affiliation><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France. Electronic address: carole.hyacinthe@u-bordeaux2.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Barraud, Quentin" sort="Barraud, Quentin" uniqKey="Barraud Q" first="Quentin" last="Barraud">Quentin Barraud</name><affiliation><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France. Electronic address: quentin.barraud@epfl.ch.</nlm:affiliation></affiliation></author><author><name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="François" last="Tison">François Tison</name><affiliation><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; Service de Neurologie, CHU de Bordeaux Haut-Lévêque, Pessac, France. Electronic address: francois.tison@chu-bordeaux.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name><affiliation><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China. Electronic address: erwan.bezard@u-bordeaux2.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Ghorayeb, Imad" sort="Ghorayeb, Imad" uniqKey="Ghorayeb I" first="Imad" last="Ghorayeb">Imad Ghorayeb</name><affiliation><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; Département de Neurophysiologie Clinique, CHU de Bordeaux Pellegrin, Bordeaux, France. Electronic address: imad.ghorayeb@u-bordeaux2.fr.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24211719</idno><idno type="pmid">24211719</idno><idno type="doi">10.1016/j.nbd.2013.10.029</idno><idno type="wicri:Area/PubMed/Corpus">000609</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000609</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism.</title><author><name sortKey="Hyacinthe, Carole" sort="Hyacinthe, Carole" uniqKey="Hyacinthe C" first="Carole" last="Hyacinthe">Carole Hyacinthe</name><affiliation><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France. Electronic address: carole.hyacinthe@u-bordeaux2.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Barraud, Quentin" sort="Barraud, Quentin" uniqKey="Barraud Q" first="Quentin" last="Barraud">Quentin Barraud</name><affiliation><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France. Electronic address: quentin.barraud@epfl.ch.</nlm:affiliation></affiliation></author><author><name sortKey="Tison, Francois" sort="Tison, Francois" uniqKey="Tison F" first="François" last="Tison">François Tison</name><affiliation><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; Service de Neurologie, CHU de Bordeaux Haut-Lévêque, Pessac, France. Electronic address: francois.tison@chu-bordeaux.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name><affiliation><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China. Electronic address: erwan.bezard@u-bordeaux2.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Ghorayeb, Imad" sort="Ghorayeb, Imad" uniqKey="Ghorayeb I" first="Imad" last="Ghorayeb">Imad Ghorayeb</name><affiliation><nlm:affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; Département de Neurophysiologie Clinique, CHU de Bordeaux Pellegrin, Bordeaux, France. Electronic address: imad.ghorayeb@u-bordeaux2.fr.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Neurobiology of disease</title><idno type="eISSN">1095-953X</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine (therapeutic use)</term><term>Analysis of Variance</term><term>Animals</term><term>Disease Models, Animal</term><term>Dopamine Agonists (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Electrocardiography</term><term>Electroencephalography</term><term>Electromyography</term><term>Female</term><term>Levodopa (therapeutic use)</term><term>Macaca fascicularis</term><term>Macaca mulatta</term><term>Parkinsonian Disorders (complications)</term><term>Parkinsonian Disorders (drug therapy)</term><term>Quinpirole (therapeutic use)</term><term>Sleep (drug effects)</term><term>Sleep Disorders, Circadian Rhythm (drug therapy)</term><term>Sleep Disorders, Circadian Rhythm (etiology)</term><term>Telemetry</term><term>Time Factors</term><term>Wakefulness (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine</term><term>Dopamine Agonists</term><term>Levodopa</term><term>Quinpirole</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Sleep</term><term>Wakefulness</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinsonian Disorders</term><term>Sleep Disorders, Circadian Rhythm</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Sleep Disorders, Circadian Rhythm</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term><term>Animals</term><term>Disease Models, Animal</term><term>Dose-Response Relationship, Drug</term><term>Electrocardiography</term><term>Electroencephalography</term><term>Electromyography</term><term>Female</term><term>Macaca fascicularis</term><term>Macaca mulatta</term><term>Telemetry</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Both excessive daytime sleepiness (EDS) and rapid eye movement (REM) sleep deregulation are part of Parkinson's disease (PD) non-motor symptoms and may complicate dopamine replacement therapy. We report here that dopamine agonists act differentially on sleep architecture in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine macaque monkey. Continuous sleep and wake electroencephalographic monitoring revealed no effect of the selective dopamine D2 receptor agonist quinpirole on EDS, whereas the selective dopamine D1 receptor agonist SKF38393 efficiently alleviated EDS and restored REM sleep to baseline values. The present results question the relevance of abandoning D1 receptor agonist treatment in PD as it might actually improve sleep-related disorders.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24211719</PMID><DateCreated><Year>2014</Year><Month>01</Month><Day>20</Day></DateCreated><DateCompleted><Year>2014</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2014</Year><Month>01</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-953X</ISSN><JournalIssue CitedMedium="Internet"><Volume>63</Volume><PubDate><Year>2014</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Neurobiology of disease</Title><ISOAbbreviation>Neurobiol. Dis.</ISOAbbreviation></Journal><ArticleTitle>D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism.</ArticleTitle><Pagination><MedlinePgn>20-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nbd.2013.10.029</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0969-9961(13)00304-5</ELocationID><Abstract><AbstractText>Both excessive daytime sleepiness (EDS) and rapid eye movement (REM) sleep deregulation are part of Parkinson's disease (PD) non-motor symptoms and may complicate dopamine replacement therapy. We report here that dopamine agonists act differentially on sleep architecture in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine macaque monkey. Continuous sleep and wake electroencephalographic monitoring revealed no effect of the selective dopamine D2 receptor agonist quinpirole on EDS, whereas the selective dopamine D1 receptor agonist SKF38393 efficiently alleviated EDS and restored REM sleep to baseline values. The present results question the relevance of abandoning D1 receptor agonist treatment in PD as it might actually improve sleep-related disorders.</AbstractText><CopyrightInformation>Copyright © 2013 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hyacinthe</LastName><ForeName>Carole</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France. Electronic address: carole.hyacinthe@u-bordeaux2.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barraud</LastName><ForeName>Quentin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France. Electronic address: quentin.barraud@epfl.ch.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tison</LastName><ForeName>François</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; Service de Neurologie, CHU de Bordeaux Haut-Lévêque, Pessac, France. Electronic address: francois.tison@chu-bordeaux.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bezard</LastName><ForeName>Erwan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China. Electronic address: erwan.bezard@u-bordeaux2.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghorayeb</LastName><ForeName>Imad</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; Département de Neurophysiologie Clinique, CHU de Bordeaux Pellegrin, Bordeaux, France. Electronic address: imad.ghorayeb@u-bordeaux2.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>11</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Dis</MedlineTA><NlmUniqueID>9500169</NlmUniqueID><ISSNLinking>0969-9961</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>20OP60125T</RegistryNumber><NameOfSubstance UI="D019257">Quinpirole</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>67287-49-4</RegistryNumber><NameOfSubstance UI="D015647">2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015647" MajorTopicYN="N">2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004562" MajorTopicYN="N">Electrocardiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004576" MajorTopicYN="N">Electromyography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008252" MajorTopicYN="N">Macaca fascicularis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008253" MajorTopicYN="N">Macaca mulatta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="N">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019257" MajorTopicYN="N">Quinpirole</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020178" MajorTopicYN="N">Sleep Disorders, Circadian Rhythm</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013686" MajorTopicYN="N">Telemetry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014851" MajorTopicYN="N">Wakefulness</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine</Keyword><Keyword MajorTopicYN="N">EDS</Keyword><Keyword MajorTopicYN="N">EEG</Keyword><Keyword MajorTopicYN="N">EMG</Keyword><Keyword MajorTopicYN="N">EOG</Keyword><Keyword MajorTopicYN="N">Excessive daytime sleepiness</Keyword><Keyword MajorTopicYN="N">MPTP</Keyword><Keyword MajorTopicYN="N">Non-human primate</Keyword><Keyword MajorTopicYN="N">PD</Keyword><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">REM</Keyword><Keyword MajorTopicYN="N">Rapid eye movement sleep</Keyword><Keyword MajorTopicYN="N">Sleep disorders</Keyword><Keyword MajorTopicYN="N">electroencephalogram</Keyword><Keyword MajorTopicYN="N">electromyogram</Keyword><Keyword MajorTopicYN="N">electrooculogram</Keyword><Keyword MajorTopicYN="N">excessive daytime sleepiness</Keyword><Keyword MajorTopicYN="N">rapid eye movement</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>08</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>10</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24211719</ArticleId><ArticleId IdType="pii">S0969-9961(13)00304-5</ArticleId><ArticleId IdType="doi">10.1016/j.nbd.2013.10.029</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000609 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000609 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24211719
|texte= D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24211719" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |